SBIA Webinar Evaluation and Certificate of Attendance April 25, 2024: Facilitating Generic Drug Product Development through Product-Specific Guidances Question Title Please provide the email address you used to register for the event: Question Title Was this event valuable to you? Yes No Question Title If you chose "Yes" to the above question why did you rate the event as valuable (choose all that apply): Event's topics were relevant to what I do I learned something new and important during this event This information will be helpful to my colleagues What I learned will have a positive impact on what I do Question Title Please rate the following statements about the speaker(s): Strongly Disagree Disagree Neutral Agree Strongly Agree Speaker adequately covered the subject Speaker adequately covered the subject Strongly Disagree Speaker adequately covered the subject Disagree Speaker adequately covered the subject Neutral Speaker adequately covered the subject Agree Speaker adequately covered the subject Strongly Agree Speaker was knowledgeable of subject matter Speaker was knowledgeable of subject matter Strongly Disagree Speaker was knowledgeable of subject matter Disagree Speaker was knowledgeable of subject matter Neutral Speaker was knowledgeable of subject matter Agree Speaker was knowledgeable of subject matter Strongly Agree Speaker answered questions clearly Speaker answered questions clearly Strongly Disagree Speaker answered questions clearly Disagree Speaker answered questions clearly Neutral Speaker answered questions clearly Agree Speaker answered questions clearly Strongly Agree Speaker adequately facilitated the session Speaker adequately facilitated the session Strongly Disagree Speaker adequately facilitated the session Disagree Speaker adequately facilitated the session Neutral Speaker adequately facilitated the session Agree Speaker adequately facilitated the session Strongly Agree Question Title Please provide any comments to help us improve future events(topics, virtual attendance suggestions, other suggestions, etc.): Next
